According to the latest information from the Hong Kong Stock Exchange, Dr. Yang Jianxin, CEO of Jishi Pharmaceutical, has purchased a total of 650,000 shares of Jishi Pharmaceutical-B (02616) for three consecutive days from June 5th to 7th, with the highest average purchase price of HKD 1.2450. The purchase amount is approximately HKD 775,000. After the increase, the latest number of holdings is approximately 64.4243 million shares, and the latest shareholding ratio is 5.02%. It is worth noting that Dr. Yang Jianxin has accumulated 3.1435 million shares in Jishi Pharmaceutical since this year.

Jishi Pharmaceutical is an innovative biopharmaceutical company dedicated to the research and development of anti-tumor drugs, committed to meeting the urgent medical needs of cancer patients in China and the world. So far, Jishi Pharmaceutical has successfully launched four innovative drugs, approved 14 new drug applications (NDA) and 9 indications. The current research and development pipeline is balanced, including 12 candidate drugs such as potential first-in-class or best-in-class antibody-drug conjugates (ADC), multispecific antibodies, immune therapies, and precision therapies.

In addition, Jishi Pharmaceutical has recently announced multiple bullish news. On June 1st, the company announced that the European Medicines Agency (EMA) Human Medicines Committee (CHMP) has issued its positive opinion recommending the approval of sugralimab combined with chemotherapy as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC). NSCLC is one of the most common cancers in the world and one of the leading causes of cancer deaths. Sugralimab is expected to become the world's first PD-L1 monoclonal antibody that covers first-line squamous and non-squamous NSCLC and is listed in Europe regardless of PD-L1 expression level. Jishi Pharmaceutical is also expected to become the first innovative biopharmaceutical company to successfully launch domestic PD-L1 monoclonal antibodies in the international market.

At the same time, the heavyweight product CS5001 (ROR1 ADC) in its R&D pipeline 2.0 for the treatment of advanced solid tumors and lymphomas has recently been published in the form of posters at the annual meeting of the American Society of Clinical Oncology for the first global multicenter human study data of phase 1a/1b. Based on the data, CS5001 demonstrated good tolerability and encouraging anti-tumor activity for multiple line-treated advanced solid tumors and lymphomas at different dose levels. It is understood that CS5001 is the first ROR1 antibody-drug conjugate (ADC) known to have observed anti-tumor activity in both solid tumors and lymphomas. The dose escalation of the global multicenter phase I trial of CS5001 is currently being carried out synchronously in the United States, Australia and China. The dose expansion study in multiple tumor types is expected to start soon, and the registration clinical trial is expected to start later this year.

In summary, Jishi Pharmaceutical is a global biomedical company that specializes in the research and innovation of pharmaceuticals. It has recently announced an increase in shareholding and bullish news in the medical and pharmaceutical field, showing its determination to meet the medical needs of cancer patients in China and around the world.